THE ART OF INJECTION

with BOTOX® Cosmetic

A step-by-step guide to your 6 key considerations when assessing and treating patients

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

Please see additional Important Safety Information on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

SUPPORTING YOUR EXPERTISE

Outlined in this guide are 6 key considerations to support your knowledge when assessing patients and treating them with BOTOX® Cosmetic.

1 START

with understanding fundamental assessment education

2 ELEVATE

your consult with 6 comprehensive best practices

3 UNDERSTAND

individualized anatomy and interrelated muscle anatomy prior to injections

4-6 INDIVIDUALIZE

approved injection points to your patient's anatomy

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS

Lack of Interchangeability Between Botulinum Toxin Products

The potency units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

Please see additional Important Safety Information on following pages.

THE *ONE* AND *ONLY* BOTOX® COSMETIC BRINGS YOU **THE LOOK OF 3**[SM1-5]

3 AREAS, 64 UNITS, AT LEAST 3 TIMES A YEAR[1]

- **Only BOTOX® Cosmetic is FDA approved** to temporarily improve the **look of 3 areas**—moderate to severe forehead lines, lateral canthal lines, and glabellar lines in adults[1-5]
- **FDA approved for 64 Units**—20 Units in forehead lines, 24 Units in lateral canthal lines, and 20 Units in glabellar lines[1]
- **Only BOTOX® Cosmetic has** been proven to deliver **consistent results** with simultaneous treatment. See your patients at least 3 times a year and schedule treatments at least 90 days apart[1]

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

1

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

ASSESS ALL 3 AREAS EVERY TIME

Ask patients to do the following to check for:

moderate to severe

Frown lines

Frown!

moderate to severe

Crow's feet lines

Smile!

moderate to severe

Forehead lines

Raise your eyebrows!

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Please see additional Important Safety Information on following pages.

Additionally, look for:

- Existing brow or lid ptosis, which may present as asymmetry in the upper face
- Which muscles act as elevators and which act as depressors
- The overall relationship between the size of your patient´s forehead and the distribution of frontalis activity
- The anatomy extent of the corrugator muscle
- How the orbicularis oculi and cheek mound move during a full smile to avoid injection of the zygomatici
- The proximity of the corrugator muscle to the levator palpebrae superioris, the muscle just beneath it

Real patient before treatment.

2

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

ELEVATE YOUR CONSULT

BUILD TRUST
with your expertise

79% of patients **receive neurotoxin** treatment **after a discussion** with their specialist.[6,*]

KNOW
what they want

Motivators to get treated vary across ages. 20-year-olds consider the safety profile.[7,†] 30-year-olds want natural-looking results.[7,‡] 40-year-olds want a brand they can trust.[8,§]

EDUCATE
on the science

Explain the underlying causes of facial lines and discuss how BOTOX® Cosmetic can temporarily reduce muscle activity to improve the appearance of facial lines.

Highlight that BOTOX® Cosmetic can provide natural-looking results in moderate to severe forehead lines, lateral cantonal lines, and glabellar lines.[1,8,9,‖,¶]

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Please see additional Important Safety Information on following pages.

VALIDATE
FDA approval of 64 Units in 3 areas

88% of patients want a product that is FDA approved (n = 526)—and 91% of millennials (n = 231) say FDA approval is very or somewhat important to them.[10,#]

Share that BOTOX® Cosmetic is backed by over 20 years of published studies reviewing its safety and efficacy.[11,12]

Reinforce, for appropriate patients, that for an aesthetically desirable result, you treat regions together because muscles are interrelated and you treat with the FDA-approved dose of 64 units.[1]

EMPHASIZE
The Look of 3[SM] with BOTOX® Cosmetic

Talk to your patients about desired outcomes with treatments of 3 areas, 64 Units, at least 3 times a year. Treatments should be spaced at least 90 days apart.[1]

Discuss that they may see results in 1 to 2 days, with full results in 30 days, and their results may last up to 4 months.[1]

Highlight that patients are satisfied with treatment results.[1,13,**]

ENCOURAGE
booking their next assessment

Schedule their visit at least 90 days out so that they can see repeatable BOTOX® Cosmetic results.

*Based on 2022 online survey of 242 healthcare professionals who answered how many patients received treatment after a discussion.[6]

†Based on a 2022 online survey of 251 neurotoxin patients, of which 40 were between the ages of 18 and 29. This subpopulation answered what drives them to BOTOX® Cosmetic.[7]

‡Based on a 2022 online survey of 251 neurotoxin patients, of which 82 were between the ages of 30 and 39. This subpopulation answered what drives them to BOTOX® Cosmetic.[7]

§Based on a 2022 online survey of 251 neurotoxin patients, of which 104 were labeled as Gen X. This subpopulation answered what drives them to BOTOX® Cosmetic.[8]

‖84% of pooled subjects (n = 592) who received 20 Units in forehead lines and glabellar lines, respectively, reported being "Very Satisfied" or "Mostly Satisfied" with the natural-looking results of treatment compared to 5.8% (n = 241) with placebo at day 30. This item was part of the Facial Line Satisfaction Questionnaire Follow-Up Treatment Satisfaction domain. In addition, 96% of market research subjects (n = 134) treated for lateral canthal lines reported they "Completely Agree" or "Somewhat Agree" that BOTOX® Cosmetic provides natural-looking results.[8,9]

¶In 2 clinical trials, 90% and 82% of patients (n = 260 each) who received 20 Units in forehead lines and glabellar lines, respectively, reported they were "Very Satisfied" or "Mostly Satisfied" (top 2 out of 5 responses) with their treatment results at day 60 vs 1% and 3%, respectively, for placebo (n = 6 total).[1]

#Based on a 2021 online survey of 526 neurotoxin patients, of which 231 were millennials. Results from respondents who replied "Very Important" or "Somewhat Important" when asked, "How important is FDA approval in cosmetic treatments?"[10]

**In 2 multicenter, double-blind, placebo-controlled studies of BOTOX® Cosmetic treatment, 90% and 82% of patients (n = 260 each) who received 20 Units in forehead lines and 20 Units in glabellar lines reported they were "Very Satisfied" or "Mostly Satisfied" (top 2 out of 5 responses) with their treatment results at day 60 vs 1% and 3%, respectively, for placebo (n = 6 total). 88% of patients (n = 313) treated with 20 Units in forehead lines, 24 Units in lateral canthal lines, and 20 Units in glabellar lines reported being "Very Satisfied" or "Mostly Satisfied" with BOTOX® Cosmetic compared to 3% with placebo (n = 156). This item was part of the Facial Line Satisfaction Questionnaire (FLSQ) Follow-Up Treatment Satisfaction domain, a validated scale from 1 to 5 where 1 = "Very Dissatisfied" and 5 = "Very Satisfied." In clinical trials, full results of treatment were seen at day 30.[1,13]

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

UNDERSTAND INDIVIDUALIZED ANATOMY AND INTERRELATED MUSCLES FOR DESIRED OUTCOMES

Consider the functional relationship of the upper face muscles.



Understanding the relevant anatomy is important for outcomes, such as variability between individuals in frontalis structure and frontal anatomy.[1,16]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Please see additional Important Safety Information on following pages.

Contraction (elevation) of the frontalis draws eyebrows superiorly and creates horizontal forehead lines.[17]

The orbicularis oculus closes the eyelid as it contracts, producing lateral canthal lines.[17]

The procerus draws down the medial brow while the corrugators draw the brow toward the midline. Repeated movements contribute to vertical glabellar lines.[17]

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

INJECTING MODERATE TO SEVERE FOREHEAD LINES

3 TYPES OF LINE PATTERNS

Most common[18]



Full forehead lines | V-shaped forehead lines | Central forehead lines

Real patient before treatment.

5 Injection Sites[1]	Total Dosage: 20 Units[1]
Middle frontalis	**4 Units**
Left lateral frontalis	**4 Units**
Right lateral frontalis	**4 Units**
Left medial frontalis	**4 Units**
Right medial frontalis	**4 Units**

20 UNITS

Treatment goal: blockage of muscle activity, leading to temporarily **improved appearance of moderate to severe forehead lines.**[1]

Real patient before treatment.

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Cardiovascular System
There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

Please see additional Important Safety Information on following pages.

INDIVIDUALIZE INJECTION POINTS TO PATIENT'S ANATOMY[1]

INJECTION PATTERN IN THE PRESCRIBING INFORMATION



These injection patterns are consistent with the approved injection pattern in the Prescribing Information, which states the lower treatment row can vary 0.5 cm to 1.5 cm medially from the palpated temporal fusion line. Injectors should assess the frontalis muscle activity when identifying the location of the appropriate injection sites.[1]

FULL PATTERN



FULL PATTERN

CENTRAL PATTERN



CENTRAL PATTERN

Real patient before treatment.

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

PRECISE INJECTION TECHNIQUES[1]

FOR MODERATE TO SEVERE FOREHEAD LINES

When identifying the location of the appropriate injection sites in the frontalis muscle, assess the overall relationship between the size of the subject's forehead and the distribution of frontalis muscle activity.

Watch step-by-step injection techniques.

Real patient before treatment.

LOCATE the following horizontal treatment rows by light palpation of the forehead at rest and maximum eyebrow elevation:

- **SUPERIOR MARGIN OF FRONTALIS ACTIVITY:** approximately 1 cm above the most superior forehead crease
- **LOWER TREATMENT ROW:** midway between the superior margin of frontalis activity and the eyebrow, at least 2 cm above the eyebrow
- **UPPER TREATMENT ROW:** midway between the superior margin of frontalis activity and lower treatment row

INJECT 4 Units/0.1 mL of reconstituted BOTOX® Cosmetic into 5 sites in the frontalis muscle for a total of 20 Units/0.5 mL. Place the 5 injections at the intersection of the horizontal treatment rows with the following vertical landmarks:

- **ON THE LOWER TREATMENT ROW:** at the midline of the face, and 0.5 cm to 1.5 cm medial to the palpated temporal fusion line (temporal crest); repeat for the other side
- **ON THE UPPER TREATMENT ROW:** midway between the lateral and medial sites on the lower treatment row; repeat for the other side

CAUTIONS AND CONSIDERATIONS

- Treat forehead lines in conjuction with glabellar lines to minimize potential for brow ptosis[1]
- Lateral injection sites can be 0.5 cm to 1.5 cm medial to the temporal fusion line, and the distance between the brow and lower treatment row should be no less than 2 cm[1]
- When targeting the corrugator, inadvertently injecting the frontalis too shallowly may lead to brow ptosis[17]

REMEMBER

The reconstituted formulation of BOTOX® Cosmetic was studied in clinical trials and is critical to achieve the correct dose. Results seen in clinical trials were achieved using the FDA-approved reconstitution process.[1]

START SEEING RESULTS IN 1 TO 2 DAYS WITH FULL RESULTS IN 30 DAYS[1]

20 Units • Moderate to severe **forehead lines (FHL)**

BEFORE

AFTER **DAY 2**

RESULTS UP TO 4 MONTHS

PRIMARY END POINT

AFTER **DAY 30**

AFTER **MONTH 4**

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

Photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic at days 2, 30, and 120. In clinical trials at day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[1] In clinical trials at day 120, approximately 40% of patients in Study 1 and approximately 32% in Study 2 achieved a grade of none or mild improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to approximately 5% of patients in Study 1 and approximately 3% in Study 2 for placebo, as assessed by investigators.[1]

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Increased Risk of Clinically Significant Effects With Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see *Warnings and Precautions*).

Please see additional Important Safety Information on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

INJECTING MODERATE TO SEVERE LATERAL CANTHAL LINES

2 TYPES OF LINE PATTERNS

Most common[19]

Full-fan pattern | Lower lid/upper cheek pattern

Real patients before treatment.

Injection Patterns 1 and 2

3 Injection Sites[1]	Total Dosage[1]: 12 Units per Side
First injection (**A**): 1.5 cm to 2 cm temporal to the lateral canthus and just temporal to the orbital rim	**4 Units**
Lateral orbicularis oculi	**4 Units**
Lateral orbicularis oculi	**4 Units**

24 UNITS

Real patient before treatment.

Treatment goal: temporary blockage of muscle activity, leading to **temporarily improved appearance of moderate to severe lateral canthal lines.**[1]

INDIVIDUALIZE INJECTION POINTS TO PATIENT'S ANATOMY[1]

INJECTION PATTERN IN THE PRESCRIBING INFORMATION

Injection pattern **1**



Injection pattern **2**



These injection patterns are consistent with the approved injection pattern in the Prescribing Information and have been individualized to each patient's unique anatomy. Injectors should assess the orbicularis oculi muscle activity when identifying the location of the appropriate injection sites.[1]

Injection pattern **1**



Injection pattern **2**

Real patients treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Dysphagia and Breathing Difficulties
Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see *Boxed Warning*).

Please see additional Important Safety Information on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 5™

PRECISE INJECTION TECHNIQUES[1]

FOR MODERATE TO SEVERE LATERAL CANTHAL LINES



Watch step-by-step injection techniques.

Real patient before treatment.

– Injections should be given with the needle bevel tip up and oriented away from the eye
– Inject 4 Units/0.1 mL into each of the 6 sites (3 injections per side) for a total dose of 24 Units

TWO APPROVED INJECTION PATTERNS

1. If lines are both above and below the lateral canthus:

- First injection: at least 1.5 cm to 2.0 cm temporal to the lateral canthus and just temporal to the lateral orbital rim
- Second injection: 1.0 cm to 1.5 cm above the first injection site and at an approximate 30° angle medially
- Third injection: 1.0 cm to 1.5 cm below the first injection site and at an approximate 30° angle medially

2. If lines are primarily below the lateral canthus:

- First injection: at least 1.5 cm to 2.0 cm temporal to the lateral canthus and just temporal to the lateral orbital rim
- Inject along a line that angles from antero inferior to super posterior
- Ensure that the most anterior injection is lateral to a line drawn vertically from the lateral canthus
- Remember to keep the most inferior injection superior to the maxillary prominence

CAUTIONS AND CONSIDERATIONS[1]

- If lateral canthal lines are above and below the lateral canthus, **use injection pattern 1**
- If lateral canthal lines are primarily below the lateral canthus, **use injection pattern 2**
- Injections should be given with the needle bevel tip up and oriented away from the eye

REMEMBER

Achieve desired outcomes with approved dosing and injection techniques.

START SEEING RESULTS IN 1 TO 2 DAYS WITH FULL RESULTS IN 30 DAYS[1]

24 Units • Moderate to severe **lateral canthal lines** (LCL)

BEFORE	AFTER **DAY 2**
	

RESULTS UP TO 4 MONTHS

PRIMARY END POINT

AFTER **DAY 30**	AFTER **MONTH 4**
	

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

Photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at days 2, 30, and 120. In clinical trials at day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[1] In clinical trials at day 120, approximately 25% of patients achieved a grade of none or mild from baseline in lateral canthal line severity at maximum smile as compared to approximately 5% in placebo, as assessed by investigators.[1]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX® Cosmetic
There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Please see additional Important Safety Information on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

INJECTING MODERATE TO SEVERE GLABELLAR LINES

4 TYPES OF LINE PATTERNS

Most common[20]



U-shaped pattern | V-shaped pattern | Converging-arrows pattern | Omega pattern

Real patients before treatment.

5 Injection Sites[1]	Total Dosage: 20 Units[1]
Procerus	**4 Units**
Left corrugator muscle—medial	**4 Units**
Left corrugator muscle—lateral	**4 Units**
Right corrugator muscle—medial	**4 Units**
Right corrugator muscle—lateral	**4 Units**

20 UNITS



Real patient before treatment.

Treatment goal: temporary blockage of muscle activity, leading to **temporarily improved appearance of moderate to severe glabellar lines.**[1]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Please see additional Important Safety Information on following pages.

INDIVIDUALIZE INJECTION POINTS TO PATIENT'S ANATOMY[1]

INJECTION PATTERN IN THE PRESCRIBING INFORMATION

These injection patterns have been adapted from the approved injection pattern in the Prescribing Information and individualized to each patient's unique anatomy. Injectors should assess the glabellar muscle activity when identifying the location of the appropriate injection sites.[1]



OMEGA-SHAPED LINES



U-SHAPED LINES



V-SHAPED LINES

Real patients treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

PRECISE INJECTION TECHNIQUES[1]

FOR MODERATE TO SEVERE GLABELLAR LINES

Watch step-by-step injection techniques.

Real patient before treatment.

INJECT 4 Units/0.1 mL into each of the 5 sites—2 in each corrugator muscle and 1 in the procerus muscle—for a total dose of 20 Units.

CAUTIONS AND CONSIDERATIONS[1]

- Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes
- Lateral corrugator injections should be placed at least 1 cm above the bony supraorbital ridge
- Ensure the injected volume/dose is accurate and, where feasible, kept to a minimum
- Do not inject neurotoxin closer than 1 cm above the central eyebrow

*Based on a 2023 online survey of 258 consumers who received BOTOX® Cosmetic within the past 6 months who agreed that they wish that they had started treatment with BOTOX® Cosmetic sooner to temporarily improve the appearance of their moderate to severe lines.[21]

REMEMBER

60% of patients say that they wish they had started treatment with BOTOX® Cosmetic sooner to temporarily improve the appearance of their moderate to severe lines.[21,*]

START SEEING RESULTS IN 1 TO 2 DAYS WITH FULL RESULTS IN 30 DAYS[1]

20 Units • Moderate to severe **glabellar lines (GL)**

BEFORE	AFTER **DAY 2**
	

RESULTS UP TO 4 MONTHS

PRIMARY END POINT

AFTER **DAY 30**	AFTER **MONTH 4**
	

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. ***Results may vary.***

Photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at days 2, 30, and 120. In clinical trials at day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[1] In clinical trials at day 120 as assessed by investigators, 25% (102/403) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 2% (2/128) in placebo. In clinical trials at day 120 as evaluated by patients, 39% (157/403) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 1% (1/128) in placebo.[1]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
ADVERSE REACTIONS

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).

Please see additional Important Safety Information on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

THE *ONE* THAT DELIVERS THE PROVEN BENEFITS YOU CAN RELY ON

#1 REQUESTED NEUROTOXIN

BOTOX® Cosmetic is the most requested neurotoxin by patients.[8,*]

2-DAY ONSET

Patients may start to see results within 1 to 2 days in all 3 areas.[1] Patients will continue to see results, with full results in 30 days.[1]

3 INDICATIONS

Only BOTOX® Cosmetic is FDA approved for the temporary improvement in the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines in adults.[1-5]

4-MONTH DURATION

BOTOX® Cosmetic provides long-lasting results up to 4 months in all 3 approved areas.[1]

*Based on a 2022 online survey of 251 patients who had received treatment with a neurotoxin within the past 2 years. Of the 48% of patients (n = 112/235) who requested treatment with a specific brand, 83% specifically requested BOTOX® Cosmetic.[8]

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
DRUG INTERACTIONS

Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.

Please see additional Important Safety Information on following page.

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3™

ADVANCE YOUR PRACTICE WITH BOTOX® COSMETIC

Only BOTOX® Cosmetic can deliver **The Look of 3**[SM1-5]

- A treatment of 3 areas, 64 Units, at least 3 times a year*
- BOTOX® Cosmetic delivers natural-looking results[1,8,9,†,‡]

Assess every patient in all 3 indicated areas, every time

- It is important to assess the entire upper face since the muscles are interrelated
- Patient anatomy is highly variable, making a thorough knowledge of facial anatomy essential[1]

Use FDA-approved and established injection techniques

- Individualize injection points to patient's anatomy
- Aesthetically desired outcomes were achieved in clinical trials using the approved dose per site[1]

FDA-approved 64 Units maximizes outcomes for appropriate patients

- Efficacy in clinical trials was based on specific dosing and injection sites
- The reconstituted formulation of BOTOX® Cosmetic was studied in clinical trials and is critical to achieve the correct dose[1]

Learn more at hcp.BotoxCosmetic.com

*Treatments should be spaced at least 90 days apart.[1]

†84% of pooled subjects (n = 592) who received 20 Units in forehead lines and glabellar lines, respectively, reported being "Very Satisfied" or "Mostly Satisfied" with the natural-looking results of treatment compared to 5.8% (n = 241) with placebo at day 30. This item was part of the Facial Line Satisfaction Questionnaire Follow-Up Treatment Satisfaction domain. In addition, 96% of market research subjects (n = 134) treated for lateral canthal lines reported they "Completely Agree" or "Somewhat Agree" that BOTOX® Cosmetic provides natural-looking results.[8,9]

‡In 2 clinical trials, 90% and 82% of patients (n = 260 each) who received 20 Units in forehead lines and glabellar lines, respectively, reported they were "Very Satisfied" or "Mostly Satisfied" (top 2 out of 5 responses) with their treatment results at day 60 vs 1% and 3%, respectively, for placebo (n = 6 total).[1]

IMPORTANT SAFETY INFORMATION (continued)
Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity

WARNINGS AND PRECAUTIONS (continued)
USE IN SPECIFIC POPULATIONS

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

Please see accompanying BOTOX® Cosmetic full Prescribing Information, including Boxed Warning, or visit https://www.rxabbvie.com/pdf/botox-cosmetic_pi.pdf

Follow us on LinkedIn

REFERENCES: 1. BOTOX® Cosmetic Prescribing Information, July 2020. 2. Dysport Prescribing Information, January 2023. 3. Xeomin Prescribing Information, September 2023. 4. Jeuveau Prescribing Information, January 2020. 5. Daxxify Prescribing Information, August 2023. 6. Data on file, Allergan Aesthetics, January 2022; HCP Facial NTX ATU. 7. Data on file, Allergan Aesthetics, May 2023; Consumer NTX A&U. 8. Data on file, Allergan Aesthetics, February 2023; Consumer NTX A&U. 9. Ogilvie P, Rivkin AZ, Dayan S, et al. Pooled subject-reported outcomes from 2 phase 3 studies of onabotulinumtoxinA for simultaneous treatment of forehead and glabellar lines. *Dermatol Surg*. 2020;46:950-957. 10. Data on file, Allergan Aesthetics, February 2021; Consumer NTX. 11. Data on file, Allergan Aesthetics, March 2022; Botulinum Toxin Peer-Reviewed Publications. 12. Data on file, Allergan Aesthetics; FDA Product Approval Information. 13. Data on file, Allergan Aesthetics, 2016; Clinical Study Report Satisfaction Table. 14. Standring S, ed. *Gray's Anatomy: The Anatomical Basis of Clinical Practice*. 40th ed. Churchill Livingstone; 2008. 15. Beer JI, Sieber DA, Scheuer JF III, Greco TM. Three-dimensional facial anatomy: structure and function as it relates to injectable neuromodulators and soft tissue fillers. *Plast Reconstr Surg Glob Open*. 2016;4(suppl 12):e1175. 16. Monheit G. Neurotoxins: Current concepts in cosmetic use on the face and neck—upper face (glabella, forehead, and crow's feet). *Plast Reconstr Surg*. 2015;136(suppl 5):72S-75S. 17. Benedetto AV, ed. *Botulinum Toxin in Clinical Dermatology*. Taylor & Francis; 2006. 18. Abramo AC, Do Amaral TP, Lessio BP, De Lima GA. Anatomy of forehead, glabellar, nasal and orbital muscles, and their correlation with distinctive patterns of skin lines on the upper third of the face: reviewing concepts. *Aesth Plast Surg*. 2016;40(6):962-971. 19. Kane MA. Classification of crow's feet patterns among Caucasian women: the key to individualizing treatment. *Plast Reconstr Surg*. 2003;112(suppl 5):33S-39S. 20. de Almeida AR, da Costa Marques ER, Banegas R, Kadunc BV. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. *Dermatol Surg*. 2012;38(9):1506-1515. 21. Data on file, Allergan Aesthetics; April 2023; BOTOX® Cosmetic Claims Assessment.

Allergan Aesthetics
an AbbVie company